ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease
September 01, 2020 07:06 ET
|
ImmunoBrain Checkpoint
ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease NEW YORK, Tuesday September 1, 2020...
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
August 27, 2020 07:59 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
August 25, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases,...
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
June 08, 2020 08:15 ET
|
Cognition Therapeutics, Inc.
New York, June 08, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Neuroprosthetics Market To Reach USD 15.8 Billion By 2026 | Reports And Data
January 14, 2020 10:01 ET
|
Reports and Data
New York, Jan. 14, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Neuroprosthetics market was valued at USD 6.1 Billion in 2018 and is expected to reach...
Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019
November 20, 2019 08:03 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Streetwise Reports Publishes 'Could There Finally Be an Effective Treatment for Alzheimer's Disease?'
November 07, 2019 07:00 ET
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Finding an effective treatment for Alzheimer's disease has been elusive as many seemingly promising avenues of research did not prove out in clinical...
Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference
September 10, 2019 08:16 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China
July 24, 2019 09:27 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
July 09, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...